Ignite Creation Date:
2024-05-05 @ 11:51 AM
Last Modification Date:
2024-10-26 @ 9:15 AM
Study NCT ID:
NCT00154544
Status:
UNKNOWN
Last Update Posted:
2005-12-20
First Post:
2005-09-09
Brief Title:
Searching for the Liver Cancer-Related Biomarkers
Sponsor:
National Taiwan University Hospital
Organization:
National Taiwan University Hospital
Study Overview
Official Title:
Identification of Biomarkers Associated With Human Hepatocellular Carcinoma by PROTEOMEX
Status:
UNKNOWN
Status Verified Date:
2003-12
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Hepatocellular carcinoma HCC has been the leading cause of cancer death in Taiwan About 6000-8000 people died of this cancer every year in Taiwan Though regular sonographic examination can early detect small HCC and there are many therapeutic modalities for HCC the therapeutic results remains unsatisfactory Though Alpha-fetoprotein AFP and des-γ-carboxy prothrombin DCP are used as the tumor markers for diagnosis of HCCs these two markers are not good enough for the early detection of small HCCs To improve the survival further investigations of the early diagnostic markers are still needed In this current project we applied the proteomic method to identify the HCC biomarkers
Detailed Description:
Cell lines Hep3B and Huh7 HCC cell lines will be cultured in Dulbeccos modified Eagle medium DMEM containing 10 fetal calf serum and incubated at 37 C in 5 CO2 incubator The rationale of using HCC cell line instead of clinical HCC samples is that HCC tissues are heterogeneous and might contain some non-HCC cells The cell will be harvested when cells reach 95 confluence
Sera collection 20 mL of venous 20 mL of venous blood was collected from 20 HBV-related HCC and 20 HCV-related HCC patients before treatment The venous blood was allowed to clot centrifuged at 800 g for 5 min and serum was aliquoted and stored at -80 0C Control sera were obtained from 20 HBV carriers without HCC 20 chronic hepatitis C patients without HCC and 10 normal subjects without liver diseases
Two-dimensional gel electrophoresis using patients sera for immunoblotting will be done Spots of interest will be identified by delayed extraction matrix-assisted laser desorption ionization
Sera collection 20 mL of venous 20 mL of venous blood was collected from 20 HBV-related HCC and 20 HCV-related HCC patients before treatment The venous blood was allowed to clot centrifuged at 800 g for 5 min and serum was aliquoted and stored at -80 0C Control sera were obtained from 20 HBV carriers without HCC 20 chronic hepatitis C patients without HCC and 10 normal subjects without liver diseases
Two-dimensional gel electrophoresis using patients sera for immunoblotting will be done Spots of interest will be identified by delayed extraction matrix-assisted laser desorption ionization
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| NSC 93-2314-B-002-228 | None | None | None |